Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) EBIT: 2024-2025

Historic EBIT for Pyxis Oncology (PYXS) over the last 2 years, with Sep 2025 value amounting to -$23.5 million.

  • Pyxis Oncology's EBIT rose 1.23% to -$23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$106.2 million, marking a year-over-year change of. This contributed to the annual value of -$89.5 million for FY2024, which is 8.84% down from last year.
  • According to the latest figures from Q3 2025, Pyxis Oncology's EBIT is -$23.5 million, which was down 18.79% from -$19.8 million recorded in Q2 2025.
  • In the past 5 years, Pyxis Oncology's EBIT registered a high of -$5.6 million during Q1 2024, and its lowest value of -$40.1 million during Q4 2024.
  • In the last 2 years, Pyxis Oncology's EBIT had a median value of -$22.9 million in 2025 and averaged -$22.2 million.
  • Data for Pyxis Oncology's EBIT shows a peak YoY increase of 1.41% (in 2025) and a maximum YoY decrease of 308.81% (in 2025) over the last 5 years.
  • Over the past 2 years, Pyxis Oncology's EBIT (Quarterly) stood at -$40.1 million in 2024, then grew by 1.23% to -$23.5 million in 2025.
  • Its EBIT was -$23.5 million in Q3 2025, compared to -$19.8 million in Q2 2025 and -$22.9 million in Q1 2025.